NEW YORK (GenomeWeb) – Thermo Fisher Scientific and BioAnalytix today announced they will develop advanced analytical profiling platforms and applications for characterizing biologic and biosimilar drugs.

Minor differences in the structures of biological drugs can significantly affect their safety and efficacy, and sophisticated analytic workflows are necessary for accurate characterization. Thermo Fisher and BioAnalytix aim to develop analytical profiling standards in order to support and accelerate the development of such therapeutics, they said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.